Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling
Leukemia ( IF 12.8 ) Pub Date : , DOI: 10.1038/leu.2017.305 G Kerdivel , , V Chesnais , E Becht , A Toma , N Cagnard , F Dumont , A Rousseau , P Fenaux , S Chevret , N Chapuis , V Boeva , W H Fridman , M Fontenay , O Kosmider
Leukemia ( IF 12.8 ) Pub Date : , DOI: 10.1038/leu.2017.305 G Kerdivel , , V Chesnais , E Becht , A Toma , N Cagnard , F Dumont , A Rousseau , P Fenaux , S Chevret , N Chapuis , V Boeva , W H Fridman , M Fontenay , O Kosmider
Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling
中文翻译:
来那度胺介导的非del(5q)骨髓增生异常综合症中的红系改善与骨髓免疫重塑有关
来那度胺介导的非del(5q)骨髓增生异常综合症中的红系改善与骨髓免疫重塑有关
更新日期:2017-10-11
Leukemia, Published online: 3 October 2017; doi:10.1038/leu.2017.305
中文翻译:
来那度胺介导的非del(5q)骨髓增生异常综合症中的红系改善与骨髓免疫重塑有关
来那度胺介导的非del(5q)骨髓增生异常综合症中的红系改善与骨髓免疫重塑有关
白血病,在线发布:2017年10月3日; doi:10.1038 / leu.2017.305